FDA advisors unanimously vote to approve Moderna's mRNA after agency drama

At a glance:

• FDA advisory committee voted 9-0 to approve Moderna's mRNA-1010 flu vaccine (mFlusiva)
• Phase 3 data showed 27% higher efficacy versus standard flu shot and stronger immune response in adults 65 and older
• Decision deadline set for August 5; CDC recommendation pending amid ACIP defunct controversy

FDA advisory committee vote and efficacy data

On Friday, the FDA’s advisory committee VRBPAC voted unanimously 9-0 to approve Moderna’s seasonal mRNA flu vaccine, designated mRNA-1010 and branded as mFlusiva. The Phase 3 trial enrolled more than 40,000 adults aged 50 and older and demonstrated a 27% increase in efficacy compared with the standard inactivated flu vaccine. A separate sub‑study of nearly 3,000 participants aged 65 and older showed that the mRNA formulation generated a more robust immune response than the high‑dose flu vaccine recommended for that age group. Committee members highlighted the platform’s agility, noting that the mRNA approach enables rapid development of seasonal formulations and better preparedness for emerging or pandemic strains. Flor Munoz‑Rivas, a pediatric infectious disease expert at Baylor College of Medicine, praised the “very well conducted” studies and “clear, robust” results, while Hayley Gans of Stanford University added that the technology “adds exciting ways” to move vaccines into the future. Both emphasized that the benefits extend beyond this season to future vaccine development.

FDA agency drama and leadership changes

In February, Trump‑appointed FDA official Vinay Prasad halted review of Moderna’s filing, claiming the trial was not adequately controlled because it lacked a comparison with a high‑dose vaccine in adults 65 and older. Despite objections from FDA scientists and career officials, Prasad’s decision left Moderna blindsided, and the agency reversed its stance the following week after a public outcry. The same official also rejected a high‑profile gene therapy for Huntington’s disease from UniQure, a move later described as “truly evil” by a former FDA official, before being pushed out of the agency at the end of April. Moderna’s CEO Stéphane Bancel welcomed the advisory committee’s support, stating that mRNA‑1010 “has the potential to provide an important new option for seasonal flu prevention” and showcases the versatility of the company’s mRNA platform. The agency has set a regulatory decision deadline of August 5, and Moderna aims to launch the vaccine later this year pending approval. The episode underscores the impact of political appointments on vaccine review timelines and public confidence.

Upcoming regulatory and CDC review process

After the FDA’s advisory vote, the vaccine must receive a recommendation from the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) before insurers and federal programs are required to cover it at no cost. However, a recent federal injunction has effectively defunct the ACIP after blocking the appointment of several anti‑vaccine allies of Health Secretary Robert F. Kennedy Jr., creating uncertainty for the recommendation process. The Department of Health and Human Services is now appealing the injunction on an expedited schedule that could extend into July, further delaying the CDC’s final guidance. Without a timely ACIP recommendation, widespread coverage and reimbursement could be delayed, affecting patient access and Moderna’s commercial rollout plans. The agency’s August 5 decision deadline adds pressure on both Moderna and the CDC to resolve the regulatory impasse before the start of the flu season. Stakeholders will be watching closely as the appeal proceeds and the CDC reassembles its advisory membership.